Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Breast Cancer Res Treat

Retrieve available abstracts of 416 articles:
HTML format
Text format



Single Articles


    June 2017
  1. PARTRIDGE AH, Sepucha K, O'Neill A, Miller KD, et al
    Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?
    Breast Cancer Res Treat. 2017 Jun 23. doi: 10.1007/s10549-017-4338.
    PubMed     Text format     Abstract available


  2. HERTZ DL, Speth KA, Kidwell KM, Gersch CL, et al
    Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.
    Breast Cancer Res Treat. 2017 Jun 22. doi: 10.1007/s10549-017-4346.
    PubMed     Text format     Abstract available


  3. ELEBRO K, Bendahl PO, Jernstrom H, Borgquist S, et al
    Androgen receptor expression and breast cancer mortality in a population-based prospective cohort.
    Breast Cancer Res Treat. 2017 Jun 22. doi: 10.1007/s10549-017-4343.
    PubMed     Text format     Abstract available


  4. THISTLE JE, Hellberg Y, Mortensen K, Hamilton-Dutoit S, et al
    The effect of 14-3-3zeta expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
    Breast Cancer Res Treat. 2017 Jun 22. doi: 10.1007/s10549-017-4289.
    PubMed     Text format     Abstract available


  5. ARTHUR R, Wang Y, Ye K, Glass AG, et al
    Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease.
    Breast Cancer Res Treat. 2017 Jun 22. doi: 10.1007/s10549-017-4347.
    PubMed     Text format     Abstract available


  6. ASKOXYLAKIS V, Kodack DP, Ferraro GB, Jain RK, et al
    Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB?
    Breast Cancer Res Treat. 2017 Jun 22. doi: 10.1007/s10549-017-4351.
    PubMed     Text format    


  7. TAN X, Camacho TF, LeBaron VT, Blackhall LJ, et al
    Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens.
    Breast Cancer Res Treat. 2017 Jun 21. doi: 10.1007/s10549-017-4348.
    PubMed     Text format     Abstract available


  8. CLARK BL, Murphy MA, Kamdem LK
    COX2 induction: a mechanism of endocrine breast cancer resistance?
    Breast Cancer Res Treat. 2017 Jun 21. doi: 10.1007/s10549-017-4284.
    PubMed     Text format     Abstract available


  9. CINTOLO-GONZALEZ JA, Braun D, Blackford AL, Mazzola E, et al
    Erratum to: Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.
    Breast Cancer Res Treat. 2017 Jun 21. doi: 10.1007/s10549-017-4349.
    PubMed     Text format    


  10. LIEDE A, Mansfield CA, Metcalfe KA, Price MA, et al
    Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.
    Breast Cancer Res Treat. 2017 Jun 17. doi: 10.1007/s10549-017-4332.
    PubMed     Text format     Abstract available


  11. YAGHJYAN L, Tamimi RM, Bertrand KA, Scott CG, et al
    Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes.
    Breast Cancer Res Treat. 2017 Jun 17. doi: 10.1007/s10549-017-4341.
    PubMed     Text format     Abstract available


  12. GOLDSTEIN LJ, Zhao F, Wang M, Swaby RF, et al
    A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Gro
    Breast Cancer Res Treat. 2017 Jun 16. doi: 10.1007/s10549-017-4310.
    PubMed     Text format     Abstract available


  13. VERNIERI C, Milano M, Mennitto A, Maggi C, et al
    Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.
    Breast Cancer Res Treat. 2017 Jun 14. doi: 10.1007/s10549-017-4336.
    PubMed     Text format     Abstract available


  14. GONCALVES R, DeSchryver K, Ma C, Tao Y, et al
    Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer.
    Breast Cancer Res Treat. 2017 Jun 13. doi: 10.1007/s10549-017-4329.
    PubMed     Text format     Abstract available


  15. PALMIERI C, Stein RC, Liu X, Hudson E, et al
    IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
    Breast Cancer Res Treat. 2017 Jun 13. doi: 10.1007/s10549-017-4328.
    PubMed     Text format     Abstract available


  16. CORTES J, Rugo HS, Awada A, Twelves C, et al
    Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
    Breast Cancer Res Treat. 2017 Jun 13. doi: 10.1007/s10549-017-4304.
    PubMed     Text format     Abstract available


  17. WINTERS H, Tielemans HJP, Hameeteman M, Paulus VAA, et al
    The efficacy of lymphaticovenular anastomosis in breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2017 Jun 12. doi: 10.1007/s10549-017-4335.
    PubMed     Text format     Abstract available


  18. YOON TI, Hwang UK, Kim ET, Lee S, et al
    Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy.
    Breast Cancer Res Treat. 2017 Jun 10. doi: 10.1007/s10549-017-4331.
    PubMed     Text format     Abstract available


  19. SOPIK V, Sun P, Narod SA
    The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
    Breast Cancer Res Treat. 2017 Jun 10. doi: 10.1007/s10549-017-4333.
    PubMed     Text format     Abstract available


  20. GLYNN RJ, Colditz GA, Tamimi RM, Chen WY, et al
    Extensions of the Rosner-Colditz breast cancer prediction model to include older women and type-specific predicted risk.
    Breast Cancer Res Treat. 2017 Jun 6. doi: 10.1007/s10549-017-4319.
    PubMed     Text format     Abstract available


  21. SHI J, Kobayashi LC, Grundy A, Richardson H, et al
    Lifetime moderate-to-vigorous physical activity and ER/PR/HER-defined post-menopausal breast cancer risk.
    Breast Cancer Res Treat. 2017 Jun 6. doi: 10.1007/s10549-017-4323.
    PubMed     Text format     Abstract available


  22. HOUSSAMI N, Turner RM, Morrow M
    Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer.
    Breast Cancer Res Treat. 2017 Jun 6. doi: 10.1007/s10549-017-4324.
    PubMed     Text format     Abstract available


  23. HEIMES AS, Madjar K, Edlund K, Battista MJ, et al
    Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer.
    Breast Cancer Res Treat. 2017 Jun 5. doi: 10.1007/s10549-017-4327.
    PubMed     Text format     Abstract available


  24. TAKANEN S, Gambirasio A, Gritti G, Kalli M, et al
    Breast cancer electron intraoperative radiotherapy: assessment of preoperative selection factors from a retrospective analysis of 758 patients and review of literature.
    Breast Cancer Res Treat. 2017 Jun 3. doi: 10.1007/s10549-017-4321.
    PubMed     Text format     Abstract available


  25. BREWER HR, Jones ME, Schoemaker MJ, Ashworth A, et al
    Family history and risk of breast cancer: an analysis accounting for family structure.
    Breast Cancer Res Treat. 2017 Jun 3. doi: 10.1007/s10549-017-4325.
    PubMed     Text format     Abstract available


  26. TURASHVILI G, Brogi E, Morrow M, Hudis C, et al
    The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
    Breast Cancer Res Treat. 2017 Jun 3. doi: 10.1007/s10549-017-4326.
    PubMed     Text format     Abstract available


  27. VIDULA N, Yau C, Li J, Esserman LJ, et al
    Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
    Breast Cancer Res Treat. 2017 Jun 2. doi: 10.1007/s10549-017-4318.
    PubMed     Text format     Abstract available


  28. KANG JW, Shin HJ, Shin KC, Chae EY, et al
    Unenhanced magnetic resonance screening using fused diffusion-weighted imaging and maximum-intensity projection in patients with a personal history of breast cancer: role of fused DWI for postoperative screening.
    Breast Cancer Res Treat. 2017 Jun 2. doi: 10.1007/s10549-017-4322.
    PubMed     Text format     Abstract available


  29. CAMPBELL JI, Yau C, Krass P, Moore D, et al
    Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Breast Cancer Res Treat. 2017 Jun 2. doi: 10.1007/s10549-017-4303.
    PubMed     Text format     Abstract available


  30. LIN C, Clark R, Tu P, Bosworth HB, et al
    Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers.
    Breast Cancer Res Treat. 2017 Jun 1. doi: 10.1007/s10549-017-4317.
    PubMed     Text format     Abstract available


  31. YOO TK, Chae BJ, Kim SJ, Lee J, et al
    Identifying long-term survivors among metastatic breast cancer patients undergoing primary tumor surgery.
    Breast Cancer Res Treat. 2017 Jun 1. doi: 10.1007/s10549-017-4309.
    PubMed     Text format     Abstract available


    May 2017
  32. FLISTER MJ, Tsaih SW, Stoddard A, Plasterer C, et al
    Host genetic modifiers of nonproductive angiogenesis inhibit breast cancer.
    Breast Cancer Res Treat. 2017 May 31. doi: 10.1007/s10549-017-4311.
    PubMed     Text format     Abstract available


  33. JUTAGIR DR, Blomberg BB, Carver CS, Lechner SC, et al
    Social well-being is associated with less pro-inflammatory and pro-metastatic leukocyte gene expression in women after surgery for breast cancer.
    Breast Cancer Res Treat. 2017 May 30. doi: 10.1007/s10549-017-4316.
    PubMed     Text format     Abstract available


  34. THOMSON CA, Chow HHS, Wertheim BC, Roe DJ, et al
    A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen.
    Breast Cancer Res Treat. 2017 May 30. doi: 10.1007/s10549-017-4292.
    PubMed     Text format     Abstract available


  35. SYROWATKA A, Motulsky A, Kurteva S, Hanley JA, et al
    Predictors of distress in female breast cancer survivors: a systematic review.
    Breast Cancer Res Treat. 2017 May 28. doi: 10.1007/s10549-017-4290.
    PubMed     Text format     Abstract available


  36. BOURKE M, Soden D, Clover AJP
    Erratum to: Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: a useful contributor to cutaneous disease control.
    Breast Cancer Res Treat. 2017 May 27. doi: 10.1007/s10549-017-4307.
    PubMed     Text format    


  37. FAN C, Georgiou KR, Morris HA, McKinnon RA, et al
    Combination breast cancer chemotherapy with doxorubicin and cyclophosphamide damages bone and bone marrow in a female rat model.
    Breast Cancer Res Treat. 2017 May 26. doi: 10.1007/s10549-017-4308.
    PubMed     Text format     Abstract available


  38. ROSELAND ME, Schwartz K, Ruterbusch JJ, Lamerato L, et al
    Influence of clinical, societal, and treatment variables on racial differences in ER-/PR- breast cancer survival.
    Breast Cancer Res Treat. 2017 May 25. doi: 10.1007/s10549-017-4300.
    PubMed     Text format     Abstract available


  39. ELLEGAARD MB, Grau C, Zachariae R, Jensen AB, et al
    Women with breast cancer report substantially more disease- and treatment-related side or late effects than registered by clinical oncologists: a cross-sectional study of a standard follow-up program in an oncological department.
    Breast Cancer Res Treat. 2017 May 23. doi: 10.1007/s10549-017-4301.
    PubMed     Text format     Abstract available


  40. KELKAR MG, Thakur B, Derle A, Chatterjee S, et al
    Tumor suppressor protein p53 exerts negative transcriptional regulation on human sodium iodide symporter gene expression in breast cancer.
    Breast Cancer Res Treat. 2017 May 20. doi: 10.1007/s10549-017-4297.
    PubMed     Text format     Abstract available


  41. EDWARDS MJ, Campbell ID, Lawrenson RA, Kuper-Hommel MJ, et al
    Influence of comorbidity on chemotherapy use for early breast cancer: systematic review and meta-analysis.
    Breast Cancer Res Treat. 2017 May 20. doi: 10.1007/s10549-017-4295.
    PubMed     Text format     Abstract available


  42. KOPANS DB
    The Canadian National Breast Screening Studies are compromised and their results are unreliable. They should not factor into decisions about breast cancer screening.
    Breast Cancer Res Treat. 2017 May 20. doi: 10.1007/s10549-017-4302.
    PubMed     Text format     Abstract available


  43. GOBEL A, Kuhlmann JD, Link T, Wimberger P, et al
    Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
    Breast Cancer Res Treat. 2017 May 19. doi: 10.1007/s10549-017-4296.
    PubMed     Text format     Abstract available


  44. RAFFERTY EA, Rose SL, Miller DP, Durand MA, et al
    Effect of age on breast cancer screening using tomosynthesis in combination with digital mammography.
    Breast Cancer Res Treat. 2017 May 18. doi: 10.1007/s10549-017-4299.
    PubMed     Text format     Abstract available


  45. YUN SJ, Ryu CW, Rhee SJ, Ryu JK, et al
    Benefit of adding digital breast tomosynthesis to digital mammography for breast cancer screening focused on cancer characteristics: a meta-analysis.
    Breast Cancer Res Treat. 2017 May 18. doi: 10.1007/s10549-017-4298.
    PubMed     Text format     Abstract available


  46. YARDLEY DA, Arrowsmith ER, Daniel BR, Eakle J, et al
    TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
    Breast Cancer Res Treat. 2017 May 15. doi: 10.1007/s10549-017-4285.
    PubMed     Text format     Abstract available


  47. GERNAAT SAM, Ho PJ, Rijnberg N, Emaus MJ, et al
    Risk of death from cardiovascular disease following breast cancer: a systematic review.
    Breast Cancer Res Treat. 2017 May 13. doi: 10.1007/s10549-017-4282.
    PubMed     Text format     Abstract available


  48. JO CHIEN A, Chambers J, Mcauley F, Kaplan T, et al
    Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
    Breast Cancer Res Treat. 2017 May 13. doi: 10.1007/s10549-017-4288.
    PubMed     Text format     Abstract available


  49. SCANNELL BRYAN M, Argos M, Andrulis IL, Hopper JL, et al
    Limited influence of germline genetic variation on all-cause mortality in women with early onset breast cancer: evidence from gene-based tests, single-marker regression, and whole-genome prediction.
    Breast Cancer Res Treat. 2017 May 13. doi: 10.1007/s10549-017-4287.
    PubMed     Text format     Abstract available


  50. RUMMEL SK, Lovejoy L, Shriver CD, Ellsworth RE, et al
    Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer.
    Breast Cancer Res Treat. 2017 May 13. doi: 10.1007/s10549-017-4291.
    PubMed     Text format     Abstract available


  51. NIEHOFF NM, White AJ, Sandler DP
    Childhood and teenage physical activity and breast cancer risk.
    Breast Cancer Res Treat. 2017 May 12. doi: 10.1007/s10549-017-4276.
    PubMed     Text format     Abstract available


  52. MAXWELL KN, Soucier-Ernst D, Tahirovic E, Troxel AB, et al
    Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 May 12. doi: 10.1007/s10549-017-4257.
    PubMed     Text format     Abstract available


  53. NERICH V, Saing S, Gamper EM, Holzner B, et al
    Critical appraisal of health-state utility values used in breast cancer-related cost-utility analyses.
    Breast Cancer Res Treat. 2017 May 11. doi: 10.1007/s10549-017-4283.
    PubMed     Text format     Abstract available


  54. LEWIS PHILLIPS GD, Nishimura MC, Lacap JA, Kharbanda S, et al
    Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
    Breast Cancer Res Treat. 2017 May 10. doi: 10.1007/s10549-017-4279.
    PubMed     Text format     Abstract available


  55. RUDDY KJ, Van Houten HK, Sangaralingham LR, Freedman RA, et al
    Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer.
    Breast Cancer Res Treat. 2017 May 10. doi: 10.1007/s10549-017-4280.
    PubMed     Text format     Abstract available


  56. CABARROU B, Mourey L, Dalenc F, Balardy L, et al
    Methodology of phase II clinical trials in metastatic elderly breast cancer: a literature review.
    Breast Cancer Res Treat. 2017 May 9. doi: 10.1007/s10549-017-4278.
    PubMed     Text format     Abstract available


  57. KIM JY, Ok ON, Seo JJ, Lee SH, et al
    A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy.
    Breast Cancer Res Treat. 2017 May 9. doi: 10.1007/s10549-017-4268.
    PubMed     Text format     Abstract available


  58. LU L, Bai Y, Wang Z
    Elevated T cell activation score is associated with improved survival of breast cancer.
    Breast Cancer Res Treat. 2017 May 9. doi: 10.1007/s10549-017-4281.
    PubMed     Text format     Abstract available


  59. HO D, Huang J, Chapman JW, Leitzel K, et al
    Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
    Breast Cancer Res Treat. 2017 May 8. doi: 10.1007/s10549-017-4273.
    PubMed     Text format     Abstract available


  60. MUFTAH AA, Aleskandarany MA, Al-Kaabi MM, Sonbul SN, et al
    Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.
    Breast Cancer Res Treat. 2017 May 6. doi: 10.1007/s10549-017-4270.
    PubMed     Text format     Abstract available


  61. JUNG SY, Ho G, Rohan T, Strickler H, et al
    Interaction of insulin-like growth factor-I and insulin resistance-related genetic variants with lifestyle factors on postmenopausal breast cancer risk.
    Breast Cancer Res Treat. 2017 May 6. doi: 10.1007/s10549-017-4272.
    PubMed     Text format     Abstract available


  62. MASALA G, Ambrogetti D, Assedi M, Bendinelli B, et al
    Mammographic breast density and breast cancer risk in a Mediterranean population: a nested case-control study in the EPIC Florence cohort.
    Breast Cancer Res Treat. 2017 May 6. doi: 10.1007/s10549-017-4274.
    PubMed     Text format     Abstract available


  63. YUAN J, Yang Y, Gao Z, Wang Z, et al
    Tyr23 phosphorylation of Anxa2 enhances STAT3 activation and promotes proliferation and invasion of breast cancer cells.
    Breast Cancer Res Treat. 2017 May 3. doi: 10.1007/s10549-017-4271.
    PubMed     Text format     Abstract available


  64. RAPHAEL J, Gandhi S, Li N, Lu FI, et al
    The role of quantitative estrogen receptor status in predicting tumor response at surgery in breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 May 2. doi: 10.1007/s10549-017-4269.
    PubMed     Text format     Abstract available


    April 2017
  65. CHRYSANTHOU E, Gorringe KL, Joseph C, Craze M, et al
    Phenotypic characterisation of breast cancer: the role of CDC42.
    Breast Cancer Res Treat. 2017 Apr 27. doi: 10.1007/s10549-017-4267.
    PubMed     Text format     Abstract available


  66. DELAHAYE LJMJ, Drukker CA, Dreezen C, Witteveen A, et al
    A breast cancer gene signature for indolent disease.
    Breast Cancer Res Treat. 2017 Apr 27. doi: 10.1007/s10549-017-4262.
    PubMed     Text format     Abstract available


  67. SHERI A, Smith IE, Hills M, Jones RL, et al
    Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Apr 26. doi: 10.1007/s10549-017-4266.
    PubMed     Text format     Abstract available


  68. LIU Y, Li ZY, Wang JN, Li X, et al
    Effects of hepatitis C virus infection on the safety of chemotherapy for breast cancer patients.
    Breast Cancer Res Treat. 2017 Apr 26. doi: 10.1007/s10549-017-4259.
    PubMed     Text format     Abstract available


  69. LOHMANN AE, Liebman MF, Brien W, Parulekar WR, et al
    Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32.
    Breast Cancer Res Treat. 2017 Apr 26. doi: 10.1007/s10549-017-4265.
    PubMed     Text format     Abstract available


  70. LOHMANN AE, Ennis M, Taylor SK, Goodwin PJ, et al
    Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls.
    Breast Cancer Res Treat. 2017 Apr 25. doi: 10.1007/s10549-017-4263.
    PubMed     Text format     Abstract available


  71. CINTOLO-GONZALEZ JA, Braun D, Blackford AL, Mazzola E, et al
    Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.
    Breast Cancer Res Treat. 2017 Apr 25. doi: 10.1007/s10549-017-4247.
    PubMed     Text format     Abstract available


  72. YOUNG-AFAT DA, van Gils CH, van den Bongard HJGD, Verkooijen HM, et al
    The Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA): objectives, design, and baseline results.
    Breast Cancer Res Treat. 2017 Apr 25. doi: 10.1007/s10549-017-4242.
    PubMed     Text format     Abstract available


  73. VON HAGENS C, Walter-Sack I, Goeckenjan M, Osburg J, et al
    Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2).
    Breast Cancer Res Treat. 2017 Apr 24. doi: 10.1007/s10549-017-4261.
    PubMed     Text format     Abstract available


  74. KAIDAR-PERSON O, Zagar TM, Oldan JD, Matney J, et al
    Early cardiac perfusion defects after left-sided radiation therapy for breast cancer: is there a volume response?
    Breast Cancer Res Treat. 2017 Apr 21. doi: 10.1007/s10549-017-4248.
    PubMed     Text format     Abstract available


  75. VAN RAMSHORST MS, Loo CE, Groen EJ, Winter-Warnars GH, et al
    MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 Apr 21. doi: 10.1007/s10549-017-4254.
    PubMed     Text format     Abstract available


  76. ALLAIRE BT, Ekwueme DU, Poehler D, Thomas CC, et al
    Breast cancer treatment costs in younger, privately insured women.
    Breast Cancer Res Treat. 2017 Apr 21. doi: 10.1007/s10549-017-4249.
    PubMed     Text format     Abstract available


  77. LIU B, Yi Z, Guan X, Zeng YX, et al
    The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis.
    Breast Cancer Res Treat. 2017 Apr 21. doi: 10.1007/s10549-017-4246.
    PubMed     Text format     Abstract available


  78. DUDENKOV TM, Ingle JN, Buzdar AU, Robson ME, et al
    SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
    Breast Cancer Res Treat. 2017 Apr 20. doi: 10.1007/s10549-017-4243.
    PubMed     Text format     Abstract available


  79. REYES ME, Fujii T, Branstetter D, Krishnamurthy S, et al
    Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.
    Breast Cancer Res Treat. 2017 Apr 17. doi: 10.1007/s10549-017-4233.
    PubMed     Text format     Abstract available


  80. SOUCISE A, Vaughn C, Thompson CL, Millen AE, et al
    Sleep quality, duration, and breast cancer aggressiveness.
    Breast Cancer Res Treat. 2017 Apr 17. doi: 10.1007/s10549-017-4245.
    PubMed     Text format     Abstract available


  81. ABDEL-RAHMAN O
    Assessment of the prognostic and discriminating value of the novel bioscore system for breast cancer; a SEER database analysis.
    Breast Cancer Res Treat. 2017 Apr 17. doi: 10.1007/s10549-017-4244.
    PubMed     Text format     Abstract available


  82. HAN J, Choi YL, Kim H, Choi JY, et al
    MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
    Breast Cancer Res Treat. 2017 Apr 13. doi: 10.1007/s10549-017-4234.
    PubMed     Text format     Abstract available


  83. BALLINGER TJ, Kassem N, Shen F, Jiang G, et al
    Discerning the clinical relevance of biomarkers in early stage breast cancer.
    Breast Cancer Res Treat. 2017 Apr 11. doi: 10.1007/s10549-017-4238.
    PubMed     Text format     Abstract available


  84. KUCHARCZYK MJ, Parpia S, Walker-Dilks C, Banfield L, et al
    Ablative Therapies in Metastatic Breast Cancer: A Systematic Review.
    Breast Cancer Res Treat. 2017 Apr 11. doi: 10.1007/s10549-017-4228.
    PubMed     Text format     Abstract available


  85. GRANT WB
    Racial disparity in vitamin D status may explain racial disparity in survival from estrogen and progesterone receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Apr 10. doi: 10.1007/s10549-017-4237.
    PubMed     Text format    


  86. ZHANG X, Brown JC, Paskett ED, Zemel BS, et al
    Changes in arm tissue composition with slowly progressive weight-lifting among women with breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2017 Apr 8. doi: 10.1007/s10549-017-4221.
    PubMed     Text format     Abstract available


  87. MONFORT SM, Pan X, Patrick R, Ramaswamy B, et al
    Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients.
    Breast Cancer Res Treat. 2017 Apr 3. doi: 10.1007/s10549-017-4230.
    PubMed     Text format     Abstract available


  88. DIECI MV, Frassoldati A, Generali D, Bisagni G, et al
    Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
    Breast Cancer Res Treat. 2017 Apr 3. doi: 10.1007/s10549-017-4219.
    PubMed     Text format    


  89. GOMEZ SL, Von Behren J, McKinley M, Clarke CA, et al
    Breast cancer in Asian Americans in California, 1988-2013: increasing incidence trends and recent data on breast cancer subtypes.
    Breast Cancer Res Treat. 2017 Apr 1. doi: 10.1007/s10549-017-4229.
    PubMed     Text format     Abstract available


  90. LEE GE, Mayer EL, Partridge A
    Prognosis of pregnancy-associated breast cancer.
    Breast Cancer Res Treat. 2017 Apr 1. doi: 10.1007/s10549-017-4224.
    PubMed     Text format     Abstract available


  91. ANDREANO A, Rebora P, Valsecchi MG, Russo AG, et al
    Adherence to guidelines and breast cancer patients survival: a population-based cohort study analyzed with a causal inference approach.
    Breast Cancer Res Treat. 2017 Apr 1. doi: 10.1007/s10549-017-4210.
    PubMed     Text format     Abstract available


    March 2017
  92. THOMAS LN, Chedrawe ER, Barnes PJ, Too CK, et al
    Prolactin/androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro.
    Breast Cancer Res Treat. 2017 Mar 31. doi: 10.1007/s10549-017-4223.
    PubMed     Text format     Abstract available


  93. MANDELBLATT JS, Cai L, Luta G, Kimmick G, et al
    Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance).
    Breast Cancer Res Treat. 2017 Mar 31. doi: 10.1007/s10549-017-4222.
    PubMed     Text format     Abstract available


  94. HAMURCU Z, Kahraman N, Ashour A, Ozpolat B, et al
    FOXM1 transcriptionally regulates expression of integrin beta1 in triple-negative breast cancer.
    Breast Cancer Res Treat. 2017 Mar 30. doi: 10.1007/s10549-017-4207.
    PubMed     Text format     Abstract available


  95. MOSHINA N, Sebuodegard S, Hofvind S
    Is breast compression associated with breast cancer detection and other early performance measures in a population-based breast cancer screening program?
    Breast Cancer Res Treat. 2017 Mar 29. doi: 10.1007/s10549-017-4214.
    PubMed     Text format     Abstract available


  96. WOLLSCHLAGER D, Merzenich H, Schwentner L, Janni W, et al
    Self-reported long-term cardiac morbidity in breast cancer patients: a retrospective cohort study in Germany (PASSOS Heart Study).
    Breast Cancer Res Treat. 2017 Mar 28. doi: 10.1007/s10549-017-4215.
    PubMed     Text format     Abstract available


  97. CICCARESE M, Fabi A, Moscetti L, Cazzaniga ME, et al
    Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
    Breast Cancer Res Treat. 2017 Mar 28. doi: 10.1007/s10549-017-4213.
    PubMed     Text format     Abstract available


  98. LIM Y, Ko ES, Han BK, Ko EY, et al
    Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer.
    Breast Cancer Res Treat. 2017 Mar 27. doi: 10.1007/s10549-017-4217.
    PubMed     Text format     Abstract available


  99. HOLCAKOVA J, Nekulova M, Orzol P, Nenutil R, et al
    DeltaNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells.
    Breast Cancer Res Treat. 2017 Mar 27. doi: 10.1007/s10549-017-4216.
    PubMed     Text format     Abstract available


  100. KRAMMER J, Pinker-Domenig K, Robson ME, Gonen M, et al
    Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2017 Mar 25. doi: 10.1007/s10549-017-4198.
    PubMed     Text format     Abstract available


  101. ASADUZZAMAN M, Constantinou S, Min H, Gallon J, et al
    Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
    Breast Cancer Res Treat. 2017 Mar 24. doi: 10.1007/s10549-017-4202.
    PubMed     Text format     Abstract available


  102. KAWAGUCHI H, Masuda N, Nakayama T, Aogi K, et al
    Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).
    Breast Cancer Res Treat. 2017 Mar 23. doi: 10.1007/s10549-017-4212.
    PubMed     Text format     Abstract available


  103. WU Y, Tran T, Dwabe S, Sarkissyan M, et al
    A83-01 inhibits TGF-beta-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells.
    Breast Cancer Res Treat. 2017 Mar 23. doi: 10.1007/s10549-017-4211.
    PubMed     Text format     Abstract available


  104. STREKALOVA E, Malin D, Rajanala H, Cryns VL, et al
    Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4201.
    PubMed     Text format     Abstract available


  105. BASELGA J, Morales SM, Awada A, Blum JL, et al
    A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4199.
    PubMed     Text format     Abstract available


  106. KIM GM, Kim S, Park HS, Kim JY, et al
    Chemotherapy-induced irreversible alopecia in early breast cancer patients.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4204.
    PubMed     Text format     Abstract available


  107. JENDRIAN S, Steffens K, Schmalfeldt B, Laakmann E, et al
    Quality of life in patients with recurrent breast cancer after second breast-conserving therapy in comparison with mastectomy: the German experience.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4208.
    PubMed     Text format     Abstract available


  108. TRYFONIDIS K, Marreaud S, Khaled H, De Valk B, et al
    Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4203.
    PubMed     Text format     Abstract available


  109. MATTER-WALSTRA K, Schwenkglenks M, Dedes KJ
    Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4209.
    PubMed     Text format    


  110. MUTI P, Secreto G, Krogh V
    Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
    Breast Cancer Res Treat. 2017 Mar 18. doi: 10.1007/s10549-017-4194.
    PubMed     Text format    


  111. FURLANETTO J, Jackisch C, Untch M, Schneeweiss A, et al
    Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69).
    Breast Cancer Res Treat. 2017 Mar 17. doi: 10.1007/s10549-017-4200.
    PubMed     Text format     Abstract available


  112. BOURKE M, Soden D, Clover AJ
    Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: a useful contributor to cutaneous disease control.
    Breast Cancer Res Treat. 2017 Mar 17. doi: 10.1007/s10549-017-4187.
    PubMed     Text format    


  113. LIM YJ, Lee SW, Choi N, Kwon J, et al
    Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice.
    Breast Cancer Res Treat. 2017 Mar 17. doi: 10.1007/s10549-017-4206.
    PubMed     Text format     Abstract available


  114. ZHANG S, Gao X, Fu W, Li S, et al
    Immunoglobulin-like domain 4-mediated ligand-independent dimerization triggers VEGFR-2 activation in HUVECs and VEGFR2-positive breast cancer cells.
    Breast Cancer Res Treat. 2017 Mar 16. doi: 10.1007/s10549-017-4189.
    PubMed     Text format     Abstract available


  115. TSENG LM, Chiu JH, Liu CY, Tsai YF, et al
    A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
    Breast Cancer Res Treat. 2017 Mar 15. doi: 10.1007/s10549-017-4195.
    PubMed     Text format     Abstract available


  116. GERSHUNI V, Li YR, Williams AD, So A, et al
    Breast cancer subtype distribution is different in normal weight, overweight, and obese women.
    Breast Cancer Res Treat. 2017 Mar 14. doi: 10.1007/s10549-017-4192.
    PubMed     Text format     Abstract available


  117. DIECI MV, Frassoldati A, Generali D, Bisagni G, et al
    Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
    Breast Cancer Res Treat. 2017 Mar 13. doi: 10.1007/s10549-017-4191.
    PubMed     Text format     Abstract available


  118. KIMMICK GG, Major B, Clapp J, Sloan J, et al
    Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).
    Breast Cancer Res Treat. 2017 Mar 10. doi: 10.1007/s10549-017-4188.
    PubMed     Text format     Abstract available


  119. YANAGAWA T, Kagara N, Miyake T, Tanei T, et al
    Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.
    Breast Cancer Res Treat. 2017 Mar 10. doi: 10.1007/s10549-017-4190.
    PubMed     Text format     Abstract available


  120. KJARTANSDOTTIR OJ, Sigurdardottir LG, Olafsdottir EJ, Jonasson JG, et al
    Estrogen-progestin use and breast cancer characteristics in lean and overweight postmenopausal women.
    Breast Cancer Res Treat. 2017 Mar 9. doi: 10.1007/s10549-017-4171.
    PubMed     Text format     Abstract available


  121. RUGO HS, Melin SA, Voigt J
    Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis.
    Breast Cancer Res Treat. 2017 Mar 8. doi: 10.1007/s10549-017-4185.
    PubMed     Text format     Abstract available


  122. CAMPANA LG, Galuppo S, Valpione S
    Treatment of cutaneous metastases of breast cancer with electrochemotherapy: what is the magnitude of clinical benefit?
    Breast Cancer Res Treat. 2017 Mar 8. doi: 10.1007/s10549-017-4186.
    PubMed     Text format    


  123. CONWAY K, Edmiston SN, Parrish E, Bryant C, et al
    Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study.
    Breast Cancer Res Treat. 2017 Mar 8. doi: 10.1007/s10549-017-4178.
    PubMed     Text format     Abstract available


  124. BINGHAM C, Fernandez SV, Fittipaldi P, Dempsey PW, et al
    Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients.
    Breast Cancer Res Treat. 2017 Mar 7. doi: 10.1007/s10549-017-4176.
    PubMed     Text format     Abstract available


  125. CORNELISSEN AJ, Kool M, Lopez Penha TR, Keuter XH, et al
    Lymphatico-venous anastomosis as treatment for breast cancer-related lymphedema: a prospective study on quality of life.
    Breast Cancer Res Treat. 2017 Mar 7. doi: 10.1007/s10549-017-4180.
    PubMed     Text format     Abstract available


  126. LEOPOLD RB, Thomas AW, Concannon KF, Correll AD, et al
    Breast cancer screening in patients with cancers other than breast.
    Breast Cancer Res Treat. 2017 Mar 6. doi: 10.1007/s10549-017-4179.
    PubMed     Text format     Abstract available


  127. ENGSTROM MJ, Valla M, Bofin AM
    Basal markers and prognosis in luminal breast cancer.
    Breast Cancer Res Treat. 2017 Mar 3. doi: 10.1007/s10549-017-4182.
    PubMed     Text format     Abstract available


  128. VADAPARAMPIL ST, Christie J, Donovan KA, Kim J, et al
    Health-related quality of life in Black breast cancer survivors with and without triple-negative breast cancer (TNBC).
    Breast Cancer Res Treat. 2017 Mar 3. doi: 10.1007/s10549-017-4173.
    PubMed     Text format     Abstract available


  129. RAUSCHER GH, Silva A, Pauls H, Frasor J, et al
    Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities.
    Breast Cancer Res Treat. 2017 Mar 1. doi: 10.1007/s10549-017-4166.
    PubMed     Text format     Abstract available


  130. SALGADO TM, Davis EJ, Farris KB, Fawaz S, et al
    Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
    Breast Cancer Res Treat. 2017 Mar 1. doi: 10.1007/s10549-017-4177.
    PubMed     Text format     Abstract available


    February 2017
  131. RAPHAEL J, Paramsothy T, Li N, Lee J, et al
    A single-institution experience of salvage therapy for patients with early and locally advanced breast cancer who progress during neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4167.
    PubMed     Text format     Abstract available


  132. MATSUDA N, Lim B, Wang Y, Krishnamurthy S, et al
    Identification of frequent somatic mutations in inflammatory breast cancer.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4165.
    PubMed     Text format     Abstract available


  133. ORUCEVIC A, Bell JL, McNabb AP, Heidel RE, et al
    Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4170.
    PubMed     Text format     Abstract available


  134. ROBERTS MC, Miller DP, Shak S, Petkov VI, et al
    Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4162.
    PubMed     Text format     Abstract available


  135. PARK HS, Sohn J, Kim SI, Park S, et al
    Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4175.
    PubMed     Text format     Abstract available


  136. CHAKRABORTY A, Hatzis C, DiGiovanna MP
    Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease.
    Breast Cancer Res Treat. 2017 Feb 24. doi: 10.1007/s10549-017-4169.
    PubMed     Text format     Abstract available


  137. YEONG J, Thike AA, Lim JC, Lee B, et al
    Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer.
    Breast Cancer Res Treat. 2017 Feb 23. doi: 10.1007/s10549-017-4161.
    PubMed     Text format     Abstract available


  138. IGNATOV T, Eggemann H, Burger E, Costa SD, et al
    Management of small T1a/b breast cancer by tumor subtype.
    Breast Cancer Res Treat. 2017 Feb 23. doi: 10.1007/s10549-017-4168.
    PubMed     Text format     Abstract available


  139. ZETTERLUND LH, Frisell J, Zouzos A, Axelsson R, et al
    Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer.
    Breast Cancer Res Treat. 2017 Feb 21. doi: 10.1007/s10549-017-4164.
    PubMed     Text format     Abstract available


  140. LIEU TA, Ray GT, Prausnitz SR, Habel LA, et al
    Oncologist and organizational factors associated with variation in breast cancer multigene testing.
    Breast Cancer Res Treat. 2017 Feb 21. doi: 10.1007/s10549-017-4158.
    PubMed     Text format     Abstract available


  141. GASTELUM GM, Iqbal C, Hilsenbeck SG, Rimawi MF, et al
    Retrospective review of genomic testing in breast cancer: Does it improve outcome?
    Breast Cancer Res Treat. 2017 Feb 21. doi: 10.1007/s10549-017-4154.
    PubMed     Text format     Abstract available


  142. VAN NIJNATTEN TJ, Simons JM, Moossdorff M, de Munck L, et al
    Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases.
    Breast Cancer Res Treat. 2017 Feb 17. doi: 10.1007/s10549-017-4157.
    PubMed     Text format     Abstract available


  143. ZETTERLUND L, Celebioglu F, Axelsson R, de Boniface J, et al
    Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer.
    Breast Cancer Res Treat. 2017 Feb 17. doi: 10.1007/s10549-017-4163.
    PubMed     Text format     Abstract available


  144. PARISE CA, Caggiano V
    Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities.
    Breast Cancer Res Treat. 2017 Feb 17. doi: 10.1007/s10549-017-4159.
    PubMed     Text format     Abstract available


  145. PARK B, Sohn JY, Yoon KA, Lee KS, et al
    Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients.
    Breast Cancer Res Treat. 2017 Feb 15. doi: 10.1007/s10549-017-4142.
    PubMed     Text format     Abstract available


  146. GOORTS B, van Nijnatten TJ, de Munck L, Moossdorff M, et al
    Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.
    Breast Cancer Res Treat. 2017 Feb 15. doi: 10.1007/s10549-017-4155.
    PubMed     Text format     Abstract available


  147. HSIEH YC, Tu SH, Su CT, Cho EC, et al
    A polygenic risk score for breast cancer risk in a Taiwanese population.
    Breast Cancer Res Treat. 2017 Feb 15. doi: 10.1007/s10549-017-4144.
    PubMed     Text format     Abstract available


  148. INWALD EC, Ortmann O, Koller M, Zeman F, et al
    Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology.
    Breast Cancer Res Treat. 2017 Feb 15. doi: 10.1007/s10549-017-4151.
    PubMed     Text format     Abstract available


  149. LERNER-ELLIS J, Donenberg T, Ahmed H, George S, et al
    A high frequency of PALB2 mutations in Jamaican patients with breast cancer.
    Breast Cancer Res Treat. 2017 Feb 13. doi: 10.1007/s10549-017-4148.
    PubMed     Text format     Abstract available


  150. HWANG KT, Kim YA, Kim J, Chu AJ, et al
    The influences of peritumoral lymphatic invasion and vascular invasion on the survival and recurrence according to the molecular subtypes of breast cancer.
    Breast Cancer Res Treat. 2017 Feb 13. doi: 10.1007/s10549-017-4153.
    PubMed     Text format     Abstract available


  151. THOMAS JS, Hanby AM, Russell N, van Tienhoven G, et al
    The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer.
    Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4145.
    PubMed     Text format     Abstract available


  152. MARINAC CR, Nelson SH, Flatt SW, Natarajan L, et al
    Sleep duration and breast cancer prognosis: perspectives from the Women's Healthy Eating and Living Study.
    Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4140.
    PubMed     Text format     Abstract available


  153. LIM EA, Gunther JE, Kim HK, Flexman M, et al
    Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients.
    Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4150.
    PubMed     Text format     Abstract available


  154. YEO SK, French R, Spada F, Clarkson R, et al
    Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells.
    Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4149.
    PubMed     Text format     Abstract available


  155. SONG SE, Shin SU, Moon HG, Ryu HS, et al
    MR imaging features associated with distant metastasis-free survival of patients with invasive breast cancer: a case-control study.
    Breast Cancer Res Treat. 2017 Feb 9. doi: 10.1007/s10549-017-4143.
    PubMed     Text format     Abstract available


  156. SHAITELMAN SF, Chiang YJ, Griffin KD, De Snyder SM, et al
    Erratum to: Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis.
    Breast Cancer Res Treat. 2017 Feb 9. doi: 10.1007/s10549-017-4116.
    PubMed     Text format    


  157. PARIKH RP, Odom EB, Yu L, Colditz GA, et al
    Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2017 Feb 9. doi: 10.1007/s10549-017-4146.
    PubMed     Text format     Abstract available


  158. TAMAKI K, Fukuyama AK, Terukina S, Kamada Y, et al
    Randomized trial of aromatherapy versus conventional care for breast cancer patients during perioperative periods.
    Breast Cancer Res Treat. 2017 Feb 8. doi: 10.1007/s10549-017-4134.
    PubMed     Text format     Abstract available


  159. RAYCHAUDHURI M, Bronger H, Buchner T, Kiechle M, et al
    MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
    Breast Cancer Res Treat. 2017 Feb 8. doi: 10.1007/s10549-017-4132.
    PubMed     Text format     Abstract available


  160. IWATA H, Masuda N, Yamamoto D, Sagara Y, et al
    Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Feb 8. doi: 10.1007/s10549-017-4138.
    PubMed     Text format     Abstract available


  161. STEINDORF K, Wiskemann J, Ulrich CM, Schmidt ME, et al
    Effects of exercise on sleep problems in breast cancer patients receiving radiotherapy: a randomized clinical trial.
    Breast Cancer Res Treat. 2017 Feb 8. doi: 10.1007/s10549-017-4141.
    PubMed     Text format     Abstract available


  162. MEHTA GA, Parker JS, Silva GO, Hoadley KA, et al
    Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer.
    Breast Cancer Res Treat. 2017 Feb 7. doi: 10.1007/s10549-017-4139.
    PubMed     Text format     Abstract available


  163. HIGGINS M, Curigliano G, Dieras V, Kuemmel S, et al
    Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.
    Breast Cancer Res Treat. 2017 Feb 7. doi: 10.1007/s10549-017-4130.
    PubMed     Text format     Abstract available


  164. CESPEDES FELICIANO EM, Kwan ML, Kushi LH, Weltzien EK, et al
    Adiposity, post-diagnosis weight change, and risk of cardiovascular events among early-stage breast cancer survivors.
    Breast Cancer Res Treat. 2017 Feb 7. doi: 10.1007/s10549-017-4133.
    PubMed     Text format     Abstract available


  165. WITZEL I, Marx AK, Muller V, Wikman H, et al
    Role of HYAL1 expression in primary breast cancer in the formation of brain metastases.
    Breast Cancer Res Treat. 2017 Feb 6. doi: 10.1007/s10549-017-4135.
    PubMed     Text format     Abstract available


  166. VALLE LF, Agarwal S, Bickel KE, Herchek HA, et al
    Hypofractionated whole breast radiotherapy in breast conservation for early-stage breast cancer: a systematic review and meta-analysis of randomized trials.
    Breast Cancer Res Treat. 2017 Feb 3. doi: 10.1007/s10549-017-4118.
    PubMed     Text format     Abstract available


  167. NYROP KA, Deal AM, Lee JT, Muss HB, et al
    Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review.
    Breast Cancer Res Treat. 2017 Feb 2. doi: 10.1007/s10549-017-4106.
    PubMed     Text format     Abstract available


  168. HAMILTON JG, Genoff MC, Salerno M, Amoroso K, et al
    Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer.
    Breast Cancer Res Treat. 2017 Feb 1. doi: 10.1007/s10549-017-4123.
    PubMed     Text format     Abstract available


  169. LEE JA, Yoo JE, Park HS
    Metabolic syndrome and incidence of breast cancer in middle-aged Korean women: a nationwide cohort study.
    Breast Cancer Res Treat. 2017 Feb 1. doi: 10.1007/s10549-017-4131.
    PubMed     Text format     Abstract available


    January 2017
  170. DETHLEFSEN C, Pedersen KS, Hojman P
    Every exercise bout matters: linking systemic exercise responses to breast cancer control.
    Breast Cancer Res Treat. 2017 Jan 30. doi: 10.1007/s10549-017-4129.
    PubMed     Text format     Abstract available


  171. CARMICHAEL H, Matsen C, Freer P, Kohlmann W, et al
    Breast cancer screening of pregnant and breastfeeding women with BRCA mutations.
    Breast Cancer Res Treat. 2017 Jan 30. doi: 10.1007/s10549-017-4122.
    PubMed     Text format     Abstract available


  172. VAN UDEN DJ, Bretveld R, Siesling S, de Wilt JH, et al
    Inflammatory breast cancer in the Netherlands; improved survival over the last decades.
    Breast Cancer Res Treat. 2017 Jan 30. doi: 10.1007/s10549-017-4119.
    PubMed     Text format     Abstract available


  173. PEREZ M, Schootman M, Hall LE, Jeffe DB, et al
    Accelerated partial breast irradiation compared with whole breast radiation therapy: a breast cancer cohort study measuring change in radiation side-effects severity and quality of life.
    Breast Cancer Res Treat. 2017 Jan 28. doi: 10.1007/s10549-017-4121.
    PubMed     Text format     Abstract available


  174. VALLA M, Engstrom MJ, Ytterhus B, Hansen AK, et al
    FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis.
    Breast Cancer Res Treat. 2017 Jan 25. doi: 10.1007/s10549-017-4125.
    PubMed     Text format     Abstract available


  175. DEN BROK WD, Speers CH, Gondara L, Baxter E, et al
    Response to "Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?"
    Breast Cancer Res Treat. 2017 Jan 21. doi: 10.1007/s10549-017-4114.
    PubMed     Text format    


  176. MA D, Jiang YZ, Liu XY, Liu YR, et al
    Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer.
    Breast Cancer Res Treat. 2017 Jan 16. doi: 10.1007/s10549-017-4113.
    PubMed     Text format     Abstract available


  177. ALTUNDAG K
    Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?
    Breast Cancer Res Treat. 2017 Jan 16. doi: 10.1007/s10549-017-4109.
    PubMed     Text format    


  178. RIZZOLO P, Silvestri V, Ottini L
    Retesting BRCA1/BRCA2 mutation negative male breast cancer patients using next generation sequencing technologies.
    Breast Cancer Res Treat. 2017 Jan 16. doi: 10.1007/s10549-017-4108.
    PubMed     Text format    


  179. MATSUO S, Watanabe J, Mitsuya K, Hayashi N, et al
    Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up.
    Breast Cancer Res Treat. 2017 Jan 13. doi: 10.1007/s10549-017-4107.
    PubMed     Text format     Abstract available


  180. GULDBERG TL, Christensen S, Zachariae R, Jensen AB, et al
    Prognostic factors in early breast cancer associated with body mass index, physical functioning, physical activity, and comorbidity: data from a nationwide Danish cohort.
    Breast Cancer Res Treat. 2017 Jan 11. doi: 10.1007/s10549-016-4099.
    PubMed     Text format     Abstract available


  181. LEONE BA, Leone J, Leone JP
    Breast cancer is a systemic disease rather than an anatomical process.
    Breast Cancer Res Treat. 2017 Jan 9. doi: 10.1007/s10549-017-4104.
    PubMed     Text format    


  182. HEO J, Chun M, Oh YT, Noh OK, et al
    Psychiatric comorbidities among breast cancer survivors in South Korea: a nationwide population-based study.
    Breast Cancer Res Treat. 2017 Jan 7. doi: 10.1007/s10549-016-4097.
    PubMed     Text format     Abstract available


  183. RADMANESH H, Spethmann T, Enssen J, Schurmann P, et al
    Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer.
    Breast Cancer Res Treat. 2017 Jan 6. doi: 10.1007/s10549-016-4100.
    PubMed     Text format     Abstract available


  184. ALTUNDAG K
    The effects of laterality in stage IV breast cancer patients at initial diagnosis; much work is needed!
    Breast Cancer Res Treat. 2017 Jan 6. doi: 10.1007/s10549-017-4103.
    PubMed     Text format    


  185. RAMANATHAN R, Olex AL, Dozmorov M, Bear HD, et al
    Angiopoietin pathway gene expression associated with poor breast cancer survival.
    Breast Cancer Res Treat. 2017 Jan 6. doi: 10.1007/s10549-017-4102.
    PubMed     Text format     Abstract available


  186. EGELAND EV, Boye K, Park D, Synnestvedt M, et al
    Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer.
    Breast Cancer Res Treat. 2017 Jan 5. doi: 10.1007/s10549-016-4096.
    PubMed     Text format     Abstract available


  187. TSANG JY, Au WL, Lo KY, Ni YB, et al
    PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Breast Cancer Res Treat. 2017 Jan 5. doi: 10.1007/s10549-016-4095.
    PubMed     Text format     Abstract available


  188. KAKUGAWA Y, Tada H, Kawai M, Suzuki T, et al
    Associations of obesity and physical activity with serum and intratumoral sex steroid hormone levels among postmenopausal women with breast cancer: analysis of paired serum and tumor tissue samples.
    Breast Cancer Res Treat. 2017 Jan 2. doi: 10.1007/s10549-016-4094.
    PubMed     Text format     Abstract available


    December 2016
  189. ECHAVARRIA I, Granja M, Bueno C, Lopez-Tarruella S, et al
    Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer.
    Breast Cancer Res Treat. 2016 Dec 31. doi: 10.1007/s10549-016-4098.
    PubMed     Text format     Abstract available


  190. OTSUJI K, Sasaki T, Tanaka A, Kunita A, et al
    Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients.
    Breast Cancer Res Treat. 2016 Dec 30. doi: 10.1007/s10549-016-4092.
    PubMed     Text format     Abstract available


  191. SHAITELMAN SF
    Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis.
    Breast Cancer Res Treat. 2016 Dec 23. doi: 10.1007/s10549-016-4089.
    PubMed     Text format     Abstract available


  192. LI Y, Kurian AW, Bondarenko I, Taylor JM, et al
    The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients.
    Breast Cancer Res Treat. 2016 Dec 23. doi: 10.1007/s10549-016-4086.
    PubMed     Text format     Abstract available


  193. PRITZLAFF M, Summerour P, McFarland R, Li S, et al
    Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
    Breast Cancer Res Treat. 2016 Dec 22. doi: 10.1007/s10549-016-4085.
    PubMed     Text format     Abstract available


  194. YAMAMOTO D, Sato N, Rai Y, Yamamoto Y, et al
    Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.
    Breast Cancer Res Treat. 2016 Dec 22. doi: 10.1007/s10549-016-4075.
    PubMed     Text format     Abstract available


  195. DE VRIES SCHULTINK AH, Alexi X, van Werkhoven E, Madlensky L, et al
    An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.
    Breast Cancer Res Treat. 2016 Dec 22. doi: 10.1007/s10549-016-4083.
    PubMed     Text format     Abstract available


  196. SHIAO J, Thomas KM, Rahimi AS, Rao R, et al
    Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients.
    Breast Cancer Res Treat. 2016 Dec 22. doi: 10.1007/s10549-016-4081.
    PubMed     Text format     Abstract available


  197. HAWLEY ST, Janz NK, Griffith KA, Jagsi R, et al
    Recurrence risk perception and quality of life following treatment of breast cancer.
    Breast Cancer Res Treat. 2016 Dec 21. doi: 10.1007/s10549-016-4082.
    PubMed     Text format     Abstract available


  198. BERTOLI G, Cava C, Diceglie C, Martelli C, et al
    MicroRNA-567 dysregulation contributes to carcinogenesis of breast cancer, targeting tumor cell proliferation, and migration.
    Breast Cancer Res Treat. 2016 Dec 20. doi: 10.1007/s10549-016-4079.
    PubMed     Text format     Abstract available


  199. DEN BROK WD, Speers CH, Gondara L, Baxter E, et al
    Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
    Breast Cancer Res Treat. 2016 Dec 20. doi: 10.1007/s10549-016-4080.
    PubMed     Text format     Abstract available


  200. LEONE BA, Vallejo CT, Romero AO, Machiavelli MR, et al
    Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  201. LI S, Liu J, Virnig BA, Collins AJ, et al
    Association between adjuvant chemotherapy and risk of acute kidney injury in elderly women diagnosed with early-stage breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  202. UHM KE, Yoo JS, Chung SH, Lee JD, et al
    Effects of exercise intervention in breast cancer patients: is mobile health (mHealth) with pedometer more effective than conventional program using brochure?
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  203. VAN GELDER M, Vanclee A, van Elssen CH, Hupperets P, et al
    Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  204. YAO S, Zhang Y, Tang L, Roh JM, et al
    Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  205. ADEMUYIWA FO, Tao Y, Luo J, Weilbaecher K, et al
    Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  206. HABRAKEN V, van Nijnatten TJ, de Munck L, Moossdorff M, et al
    Does the TNM classification of solitary internal mammary lymph node metastases in breast cancer still apply?
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  207. ZICK SM, Colacino J, Cornellier M, Khabir T, et al
    Fatigue reduction diet in breast cancer survivors: a pilot randomized clinical trial.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  208. TAVERA-TAPIA A, Perez-Cabornero L, Macias JA, Ceballos MI, et al
    Almost 2% of Spanish breast cancer families are associated to germline pathogenic mutations in the ATM gene.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  209. CHUNG YR, Kim HJ, Jang MH, Park SY, et al
    Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    November 2016
  210. SAITO R, Miki Y, Hata S, Ishida T, et al
    Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  211. LI X, Yang J, Peng L, Sahin AA, et al
    Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  212. SAGARA A, Igarashi K, Otsuka M, Kodama A, et al
    Endocan as a prognostic biomarker of triple-negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  213. WANG RX, Chen S, Jin X, Chen CM, et al
    Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  214. ELSHOF LE, Schaapveld M, Schmidt MK, Rutgers EJ, et al
    Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  215. BOURKE MG, Salwa SP, Sadadcharam M, Whelan MC, et al
    Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: Ten-year audit of single centre experience.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  216. FREEDMAN RA, Seisler DK, Foster JC, Sloan JA, et al
    Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  217. ALTUNDAG K
    First-line all-oral NORCAP (vinorelbine/capecitabine) might be alternative to taxane-based chemotherapy for HER2-negative metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  218. HUANG J, Woods P, Normolle D, Goff JP, et al
    Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  219. SHI M, O'Brien KM, Sandler DP, Taylor JA, et al
    Previous GWAS hits in relation to young-onset breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  220. MCNAMARA KM, Oguro S, Omata F, Kikuchi K, et al
    The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  221. CONNOR AE, Visvanathan K, Baumgartner KB, Baumgartner RN, et al
    Pre-diagnostic breastfeeding, adiposity, and mortality among parous Hispanic and non-Hispanic white women with invasive breast cancer: the Breast Cancer Health Disparities Study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  222. MASALA G, Bendinelli B, Assedi M, Occhini D, et al
    Up to one-third of breast cancer cases in post-menopausal Mediterranean women might be avoided by modifying lifestyle habits: the EPIC Italy study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  223. CALIP GS, Elmore JG, Boudreau DM
    Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  224. AMARA D, Wolf DM, van 't Veer L, Esserman L, et al
    Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  225. CHOWDHURY M, Euhus D, Onega T, Biswas S, et al
    A model for individualized risk prediction of contralateral breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  226. BRAUNSTEIN LZ, Taghian AG, Niemierko A, Salama L, et al
    Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  227. JANKOWSKI C, Guiu S, Cortet M, Charon-Barra C, et al
    Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  228. MERZENICH H, Bartkowiak D, Schmidberger H, Schmidt M, et al
    3D conformal radiotherapy is not associated with the long-term cardiac mortality in breast cancer patients: a retrospective cohort study in Germany (PASSOS-Heart Study).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    October 2016
  229. HARBECK N, Saupe S, Jager E, Schmidt M, et al
    A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  230. MORAN O, Nikitina D, Royer R, Poll A, et al
    Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  231. HAMDI Y, Soucy P, Kuchenbaeker KB, Pastinen T, et al
    Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  232. IQBAL J, Ginsburg O, Giannakeas V, Rochon PA, et al
    The impact of nodal micrometastasis on mortality among women with early-stage breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  233. JANSSEN N, Fortis SP, Speigl L, Haritos C, et al
    Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  234. GAUTAM J, Bae YK, Kim JA
    Up-regulation of cathepsin S expression by HSP90 and 5-HT7 receptor-dependent serotonin signaling correlates with triple negativity of human breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  235. CHLEBOWSKI RT, Pan K, Col NF
    Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  236. FERNANDES R, Mazzarello S, Stober C, Vandermeer L, et al
    Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  237. KIM H, Cho DY, Choi DH, Oh M, et al
    Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  238. KOTSOPOULOS J, Singer C, Narod SA
    Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  239. DUGUE PA, Milne RL, Southey MC
    A prospective study of peripheral blood DNA methylation at RPTOR, MGRN1 and RAPSN and risk of breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  240. WANG C, Mu Z, Chervoneva I, Austin L, et al
    Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  241. CHENG F, Zhao J, Hanker AB, Brewer MR, et al
    Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  242. NEUHOUSER ML, Smith AW, George SM, Gibson JT, et al
    Use of complementary and alternative medicine and breast cancer survival in the Health, Eating, Activity, and Lifestyle Study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  243. SCHONBERG MA, Li VW, Eliassen AH, Davis RB, et al
    Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  244. PETRELLI F, Barni S, Bregni G, de Braud F, et al
    Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  245. CHURILLA TM, Egleston BL, Murphy CT, Sigurdson ER, et al
    Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  246. LEE JS, Magbanua MJ, Park JW
    Circulating tumor cells in breast cancer: applications in personalized medicine.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  247. BRZEZINSKA M, Williams LJ, Thomas J, Michael Dixon J, et al
    Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  248. DICKENS C, Pfeiffer RM, Anderson WF, Duarte R, et al
    Investigation of breast cancer sub-populations in black and white women in South Africa.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  249. CHEON H, Kim HJ, Lee SW, Kim DH, et al
    Internal mammary node adenopathy on breast MRI and PET/CT for initial staging in patients with operable breast cancer: prevalence and associated factors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  250. CAZZANIGA ME, Cortesi L, Ferzi A, Scaltriti L, et al
    Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  251. HENNIGS A, Riedel F, Marme F, Sinn P, et al
    Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  252. LANCZKY A, Nagy A, Bottai G, Munkacsy G, et al
    miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  253. VAN MAAREN MC, de Munck L, Jobsen JJ, Poortmans P, et al
    Breast-conserving therapy versus mastectomy in T1-2N2 stage breast cancer: a population-based study on 10-year overall, relative, and distant metastasis-free survival in 3071 patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  254. LI Z, Heng J, Yan J, Guo X, et al
    Integrated analysis of gene expression and methylation profiles of 48 candidate genes in breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  255. NORDENSKJOLD A, Fohlin H, Fornander T, Lofdahl B, et al
    Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  256. REIX N, Malina C, Chenard MP, Bellocq JP, et al
    A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  257. HERVIK JB, Stub T
    Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: A systematic review and meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  258. GOLSHAN M, Cirrincione CT, Sikov WM, Carey LA, et al
    Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  259. POLLOCK YG, Blackford AL, Jeter SC, Wright J, et al
    Adjuvant radiation use in older women with early-stage breast cancer at Johns Hopkins.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  260. ELSHOF LE, Schaapveld M, Schmidt MK, Rutgers EJ, et al
    Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.
    Breast Cancer Res Treat. 2016;159:553-63.
    PubMed     Text format     Abstract available


  261. DEUTSCH TM, Riethdorf S, Nees J, Hartkopf AD, et al
    Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  262. ALIMUJIANG A, Mo M, Liu Y, Huang NS, et al
    The association between China's Great famine and risk of breast cancer according to hormone receptor status: a hospital-based study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    September 2016
  263. LEOPOLD C, Wagner AK, Zhang F, Lu CY, et al
    Erratum to: Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  264. ARISTEI C, Kaidar-Person O, Arenas M, Coles C, et al
    The 2016 Assisi Think Tank Meeting on breast cancer: white paper.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  265. HARTMAN EK, Eslick GD
    The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  266. TIAINEN S, Oikari S, Tammi M, Rilla K, et al
    High extent of O-GlcNAcylation in breast cancer cells correlates with the levels of HAS enzymes, accumulation of hyaluronan, and poor outcome.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  267. VAN DER POL CC, Lacle MM, Witkamp AJ, Kornegoor R, et al
    Prognostic models in male breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  268. BEABER EF, Tosteson AN, Haas JS, Onega T, et al
    Breast cancer screening initiation after turning 40 years of age within the PROSPR consortium.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  269. YANG EJ, Ahn S, Kim EK, Kang E, et al
    Use of a prospective surveillance model to prevent breast cancer treatment-related lymphedema: a single-center experience.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  270. KONO M, Fujii T, Lyons GR, Huo L, et al
    Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  271. ZHENG Q, Xia W, Lu Q, Hong R, et al
    Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  272. JOHNSTON S, Basik M, Hegg R, Lausoontornsiri W, et al
    Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naive advanced breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  273. DIABY V, Adunlin G, Ali AA, Zeichner SB, et al
    Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  274. CEJALVO JM, Perez-Fidalgo JA, Ribas G, Burgues O, et al
    Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  275. ENG LG, Dawood S, Sopik V, Haaland B, et al
    Ten-year survival in women with primary stage IV breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  276. FREDHOLM H, Magnusson K, Lindstrom LS, Garmo H, et al
    Long-term outcome in young women with breast cancer: a population-based study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  277. CATUCCI I, Casadei S, Ding YC, Volorio S, et al
    Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  278. TSUYUKI S, Senda N, Kanng Y, Yamaguchi A, et al
    Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  279. SISCO M, Kyrillos AM, Lapin BR, Wang CE, et al
    Trends and variation in the use of nipple-sparing mastectomy for breast cancer in the United States.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  280. O'SULLIVAN CC, Lindenberg M, Bryla C, Patronas N, et al
    ANG1005 for breast cancer brain metastases: correlation between 18F-FLT-PET after first cycle and MRI in response assessment.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  281. O'NEAL J, Clem A, Reynolds L, Dougherty S, et al
    Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  282. HAINSWORTH JD, Murphy PB, Alemar JR, Daniel BR, et al
    Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  283. RAPHAEL MJ, Biagi JJ, Kong W, Mates M, et al
    The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  284. WONG EM, Joo JE, McLean CA, Baglietto L, et al
    Analysis of the breast cancer methylome using formalin-fixed paraffin-embedded tumour.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  285. DETHLEFSEN C, Lillelund C, Midtgaard J, Andersen C, et al
    Exercise regulates breast cancer cell viability: systemic training adaptations versus acute exercise responses.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  286. SAMUEL CA, Pinheiro LC, Reeder-Hayes KE, Walker JS, et al
    To be young, Black, and living with breast cancer: a systematic review of health-related quality of life in young Black breast cancer survivors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  287. HAMY AS, Bieche I, Lehmann-Che J, Scott V, et al
    BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  288. RYU JM, Lee HJ, Yoon TI, Lee ES, et al
    Breast cancer-specific mortality in small-sized tumor with node-positive breast cancer: a nation-wide study in Korean breast cancer society.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  289. PINHEIRO LC, Samuel CA, Reeder-Hayes KE, Wheeler SB, et al
    Understanding racial differences in health-related quality of life in a population-based cohort of breast cancer survivors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    August 2016
  290. COHN BA, Terry MB, Plumb M, Cirillo PM, et al
    Erratum to: Exposure to polychlorinated biphenyl (PCB) congeners measured shortly after giving birth and subsequent risk of maternal breast cancer before age 50.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  291. YOUNIS T, Rayson D, Jovanovic S, Skedgel C, et al
    Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  292. NERICH V, Saing S, Gamper EM, Kemmler G, et al
    Cost-utility analyses of drug therapies in breast cancer: a systematic review.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  293. FENG J, Xu G, Liu J, Zhang N, et al
    Phosphorylation of LSD1 at Ser112 is crucial for its function in induction of EMT and metastasis in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  294. LE QA, Bae YH, Kang JH
    Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  295. XU M, Xu Y, Chen M, Li Y, et al
    Association study confirms two susceptibility loci for breast cancer in Chinese Han women.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  296. NUNES RA, Wray L, Mete M, Herbolsheimer P, et al
    Genomic profiling of breast cancer in African-American women using MammaPrint.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  297. SHIEH Y, Hu D, Ma L, Huntsman S, et al
    Breast cancer risk prediction using a clinical risk model and polygenic risk score.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  298. LI T, Mello-Thoms C, Brennan PC
    Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  299. LI N, Thompson ER, Rowley SM, McInerny S, et al
    Reevaluation of RINT1 as a breast cancer predisposition gene.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  300. LEE DH, Park S, Lim SM, Lee MK, et al
    Resting heart rate as a prognostic factor for mortality in patients with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available



  301. UK Breast Cancer Research Symposium 2016: Submitted Abstracts.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  302. ROGERS LQ, Courneya KS, Carter SJ, Anton PM, et al
    Effects of a multicomponent physical activity behavior change intervention on breast cancer survivor health status outcomes in a randomized controlled trial.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  303. VAN RAMSHORST MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, et al
    Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  304. HARANO K, Lei X, Gonzalez-Angulo AM, Murthy RK, et al
    Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  305. VERSCHOOR AM, Kuijer A, Verloop J, Van Gils CH, et al
    Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  306. GONG Z, Hong CC, Bandera EV, Adams-Campbell LL, et al
    Vigorous physical activity and risk of breast cancer in the African American breast cancer epidemiology and risk consortium.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  307. ALESKANDARANY MA, Abduljabbar R, Ashankyty I, Elmouna A, et al
    Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  308. FARVID MS, Cho E, Eliassen AH, Chen WY, et al
    Lifetime grain consumption and breast cancer risk.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  309. BAO T, Basal C, Seluzicki C, Li SQ, et al
    Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  310. PARSONS BM, Landercasper J, Smith AL, Go RS, et al
    21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  311. LI F, Armato SG, Giger ML, MacMahon H, et al
    Clinical significance of noncalcified lung nodules in patients with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  312. VALACHIS A, Garmo H, Weinman J, Fredriksson I, et al
    Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  313. FIGUEROA JD, Pfeiffer RM, Brinton LA, Palakal MM, et al
    Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case-control study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  314. JOHANSSON H, Gandini S, Serrano D, Gjerde J, et al
    A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  315. NARAYAN AK, Visvanathan K, Harvey SC
    Comparative effectiveness of breast MRI and mammography in screening young women with elevated risk of developing breast cancer: a retrospective cohort study.
    Breast Cancer Res Treat. 2016;158:583-9.
    PubMed     Text format     Abstract available


  316. SLIJKHUIS WA, Noorda EM, van der Zaag-Loonen H, Eenennaam MJ, et al
    Ultrasound-guided breast-conserving surgery for early-stage palpable and nonpalpable invasive breast cancer: decreased excision volume at unchanged tumor-free resection margin.
    Breast Cancer Res Treat. 2016;158:535-41.
    PubMed     Text format     Abstract available


  317. BEEK MA, Gobardhan PD, Schoenmaeckers EJ, Klompenhouwer EG, et al
    Axillary reverse mapping in axillary surgery for breast cancer: an update of the current status.
    Breast Cancer Res Treat. 2016;158:421-32.
    PubMed     Text format     Abstract available


  318. HALPERN MT, Schrag D
    Effects of state-level medicaid policies and patient characteristics on time to breast cancer surgery among medicaid beneficiaries.
    Breast Cancer Res Treat. 2016;158:573-81.
    PubMed     Text format     Abstract available


    July 2016
  319. TABUNG FK, Steck SE, Liese AD, Zhang J, et al
    Patterns of change over time and history of the inflammatory potential of diet and risk of breast cancer among postmenopausal women.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  320. SCHOTT AF, Barlow WE, Van Poznak CH, Hayes DF, et al
    Phase II studies of two different schedules of dasatinib in ***bone metastasis predominant metastatic breast cancer: SWOG S0622.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  321. DONENBERG T, Ahmed H, Royer R, Zhang S, et al
    A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  322. LEOPOLD C
    Author's response to "letter to the editor: lower vitamin D status may explain racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer".
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  323. ALSHAREEDA AT, Negm OH, Aleskandarany MA, Green AR, et al
    Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  324. KEHL KL, Shen C, Litton JK, Arun B, et al
    Erratum to: Rates of BRCA1/2 mutation testing among young survivors of breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  325. GENNARI A, Amadori D, Scarpi E, Farolfi A, et al
    Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  326. ROGAN S, Taeymans J, Luginbuehl H, Aebi M, et al
    Therapy modalities to reduce lymphoedema in female breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  327. QIAN XL, Wen HY, Yang YL, Gu F, et al
    Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  328. GRANT WB
    Lower vitamin D status may explain racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  329. GREEN AR, Soria D, Powe DG, Nolan CC, et al
    Erratum to: Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  330. KWAN ML, Yao S, Lee VS, Roh JM, et al
    Race/ethnicity, genetic ancestry, and breast cancer-related lymphedema in the Pathways Study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  331. WARNER ET, Ballman KV, Strand C, Boughey JC, et al
    Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  332. MURANEN TA, Mavaddat N, Khan S, Fagerholm R, et al
    Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  333. LEE PE, Tierney MC, Wu W, Pritchard KI, et al
    Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  334. BATTAGLIA TA, Darnell JS, Ko N, Snyder F, et al
    The impact of patient navigation on the delivery of diagnostic breast cancer care in the National Patient Navigation Research Program: a prospective meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  335. LO-FO-WONG DN, de Haes HC, Aaronson NK, van Abbema DL, et al
    Predictors of enduring clinical distress in women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  336. AHMAD A, Wang Z, Kong D, Ali S, et al
    Retraction Note to: FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  337. AHMAD A, Wang Z, Kong D, Ali R, et al
    Retraction Note to: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  338. BRENTNALL AR, Cuzick J, Byers H, Segal C, et al
    Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  339. YE ZJ, Liang MZ, Qiu HZ, Liu ML, et al
    Effect of a multidiscipline mentor-based program, Be Resilient to Breast Cancer (BRBC), on female breast cancer survivors in mainland China-A randomized, controlled, theoretically-derived intervention trial.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  340. ADAMS SC, Segal RJ, McKenzie DC, Vallerand JR, et al
    Impact of resistance and aerobic exercise on sarcopenia and dynapenia in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  341. SECRETO G, Sieri S, Agnoli C, Grioni S, et al
    A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  342. NAHLEH ZA, Barlow WE, Hayes DF, Schott AF, et al
    SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  343. ZHANG J, Sun J, Chen J, Yao L, et al
    Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  344. GARONA J, Alonso DF
    Perioperative biology in primary breast cancer: selective targeting of vasopressin type 2 receptor using desmopressin as a novel therapeutic approach.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  345. GIULIANI O, Mancini S, Puliti D, Caranci N, et al
    Patterns and determinants of receipt of follow-up mammography and/or clinical examination in a cohort of Italian breast cancer survivors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  346. SOPIK V, Iqbal J, Sun P, Narod SA, et al
    Impact of a prior diagnosis of DCIS on survival from invasive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  347. ALESKANDARANY MA, Green AR, Ashankyty I, Elmouna A, et al
    Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  348. YANG M, Teng W, Qu Y, Wang H, et al
    Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  349. VEERARAGHAVAN J, Ma J, Hu Y, Wang XS, et al
    Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  350. PRUNERI G, Gray KP, Vingiani A, Viale G, et al
    Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  351. KOTOULA V, Karavasilis V, Zagouri F, Kouvatseas G, et al
    Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    June 2016
  352. VAN RAMSHORST MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, et al
    The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  353. LAN ZJ, Hu Y, Zhang S, Li X, et al
    GGNBP2 acts as a tumor suppressor by inhibiting estrogen receptor alpha activity in breast cancer cells.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  354. LEOPOLD C, Wagner AK, Zhang F, Lu CY, et al
    Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  355. BRIGHT EE, Petrie KJ, Partridge AH, Stanton AL, et al
    Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  356. NYROP KA, Williams GR, Muss HB, Shachar SS, et al
    Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  357. FREEDMAN RA, Viswanath K, Vaz-Luis I, Keating NL, et al
    Learning from social media: utilizing advanced data extraction techniques to understand barriers to breast cancer treatment.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  358. SUH KJ, Ryu HS, Lee KH, Kim H, et al
    Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  359. TIWARI SR, Mishra P, Raska P, Calhoun B, et al
    Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  360. DOEBAR SC, van den Broek EC, Koppert LB, Jager A, et al
    Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  361. KUROZUMI S, Padilla M, Kurosumi M, Matsumoto H, et al
    HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  362. ZEITZER JM, Nouriani B, Rissling MB, Sledge GW, et al
    Aberrant nocturnal cortisol and disease progression in women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  363. COLACINO JA, McDermott SP, Sartor MA, Wicha MS, et al
    Transcriptomic profiling of curcumin-treated human breast stem cells identifies a role for stearoyl-coa desaturase in breast cancer prevention.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  364. DILLEKAS H, Demicheli R, Ardoino I, Jensen SA, et al
    The recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  365. SMYTH LM, Iyengar NM, Chen MF, Popper SM, et al
    Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  366. HICKEY M, Marino JL, Braat S, Wong S, et al
    A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  367. KEINAN-BOKER L, Levine H, Derazne E, Molina-Hazan V, et al
    Measured adolescent body mass index and adult breast cancer in a cohort of 951,480 women.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  368. HIRKO KA, Fortner RT, Hankinson SE, Wu T, et al
    Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses' Health Study and Nurses' Health Study II.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  369. ARUN BK, Gong Y, Liu D, Litton JK, et al
    Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  370. WANG SY, Long JB, Killelea BK, Evans SB, et al
    Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  371. NEUGUT AI, Hillyer GC, Kushi LH, Lamerato L, et al
    A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  372. HEIN A, Gass P, Walter CB, Taran FA, et al
    Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  373. MATTER-WALSTRA K, Ruhstaller T, Klingbiel D, Schwenkglenks M, et al
    Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  374. GONG IY, Verma S, Yan AT, Ko DT, et al
    Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  375. MUNIZ J, Kidwell KM, Henry NL
    Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assay.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  376. DI MEGLIO A, Freedman RA, Lin NU, Barry WT, et al
    Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  377. ROBLES AJ, Cai S, Cichewicz RH, Mooberry SL, et al
    Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  378. YAO H, Veine DM, Livant DL
    Therapeutic inhibition of breast cancer bone metastasis progression and lung colonization: breaking the vicious cycle by targeting alpha5beta1 integrin.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  379. AKINYEMIJU T, Moore JX, Ojesina AI, Waterbor JW, et al
    Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  380. ZHOU Y, Ouyang T, Xie Y, Wang T, et al
    A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  381. SZALAYOVA G, Ogrodnik A, Spencer B, Wade J, et al
    Human breast cancer biopsies induce eosinophil recruitment and enhance adjacent cancer cell proliferation.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    May 2016
  382. CHEN Y, Jiang L, Gao B, Cheng ZY, et al
    Survival and disease-free benefits with mastectomy versus breast conservation therapy for early breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  383. KWON JS, Pansegrau G, Nourmoussavi M, Hammond G, et al
    Long-term consequences of ovarian ablation for premenopausal breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  384. LIU YL, Saraf A, Lee SM, Zhong X, et al
    Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  385. LEWIN R, Sulkes A, Shochat T, Tsoref D, et al
    Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  386. WIRTZ RM, Sihto H, Isola J, Heikkila P, et al
    Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  387. CHEN L, Cook LS, Tang MC, Porter PL, et al
    Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  388. ORUCEVIC A, Heidel RE, Bell JL
    Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  389. BOQUIREN VM, Hack TF, Thomas RL, Towers A, et al
    A longitudinal analysis of chronic arm morbidity following breast cancer surgery.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  390. VILLARREAL-GARZA C, Bargallo-Rocha JE, Soto-Perez-de-Celis E, Lasa-Gonsebatt F, et al
    Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  391. ZHOU W, Zhao Y, Pan H, Li Q, et al
    Great tumour burden in the axilla may influence lymphatic drainage in breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  392. SINGH K, Tantravahi U, Lomme MM, Pasquariello T, et al
    Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HE
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  393. SULAICA E, Han T, Wang W, Bhat R, et al
    Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  394. CHEN X, Hu H, He L, Yu X, et al
    A novel subtype classification and risk of breast cancer by histone modification profiling.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  395. HUO J, Smith BD, Giordano SH, Reece GP, et al
    Post-mastectomy breast reconstruction and its subsequent complications: a comparison between obese and non-obese women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  396. JACOT W, Pons E, Frenel JS, Guiu S, et al
    Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  397. SCHMIDT N, Jacob L, Coleman R, Kostev K, et al
    Erratum to: The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  398. WISE R, Duhachek-Muggy S, Qi Y, Zolkiewski M, et al
    Protein disulfide isomerases in the endoplasmic reticulum promote anchorage-independent growth of breast cancer cells.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  399. BUSTREO S, Osella-Abate S, Cassoni P, Donadio M, et al
    Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  400. SUN F, Skolny MN, Swaroop MN, Rawal B, et al
    The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    April 2016
  401. VAN ROOZENDAAL LM, Goorts B, Klinkert M, Keymeulen KB, et al
    Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.
    Breast Cancer Res Treat. 2016;156:517-25.
    PubMed     Text format     Abstract available


  402. AUMANN K, Niermann K, Asberger J, Wellner U, et al
    Structured reporting ensures complete content and quick detection of essential data in pathology reports of oncological breast resection specimens.
    Breast Cancer Res Treat. 2016;156:495-500.
    PubMed     Text format     Abstract available


  403. EVANS CN, Brewer NT, Vadaparampil ST, Boisvert M, et al
    Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy.
    Breast Cancer Res Treat. 2016;156:549-55.
    PubMed     Text format     Abstract available


  404. LIM ST, Choi JE, Kim SJ, Kim HA, et al
    Prognostic implication of the tumor location according to molecular subtypes in axillary lymph node-positive invasive ductal cancer in a Korean population.
    Breast Cancer Res Treat. 2016;156:473-83.
    PubMed     Text format     Abstract available


    February 2016
  405. FAN YS, Casas CE, Peng J, Watkins M, et al
    HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Breast Cancer Res Treat. 2016;155:457-62.
    PubMed     Text format     Abstract available


  406. EVANS DG, Lalloo F, Howell S, Verhoef S, et al
    Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.
    Breast Cancer Res Treat. 2016;155:597-601.
    PubMed     Text format     Abstract available


  407. CHIEN AJ, Cockerill A, Fancourt C, Schmidt E, et al
    A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
    Breast Cancer Res Treat. 2016;155:521-30.
    PubMed     Text format     Abstract available


  408. MILLER CL, Coopey SB, Rafferty E, Gadd M, et al
    Comparison of intra-operative specimen mammography to standard specimen mammography for excision of non-palpable breast lesions: a randomized trial.
    Breast Cancer Res Treat. 2016;155:513-9.
    PubMed     Text format     Abstract available


  409. SHAPIRO AC, Adlis SA, Robien K, Kirstein MN, et al
    Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
    Breast Cancer Res Treat. 2016;155:501-12.
    PubMed     Text format     Abstract available


  410. JONGEN L, Paridaens R, Floris G, Wildiers H, et al
    Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm.
    Breast Cancer Res Treat. 2016;155:603-7.
    PubMed     Text format     Abstract available


  411. KNOBF MT, Jeon S, Smith B, Harris L, et al
    Effect of a randomized controlled exercise trial on bone outcomes: influence of adjuvant endocrine therapy.
    Breast Cancer Res Treat. 2016;155:491-500.
    PubMed     Text format     Abstract available


  412. SHEFFIELD BS, Kos Z, Asleh-Aburaya K, Wang XQ, et al
    Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Breast Cancer Res Treat. 2016;155:483-90.
    PubMed     Text format     Abstract available


  413. HASSETT MJ, Jiang W, Habel LA, Nekhlyudov L, et al
    Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community.
    Breast Cancer Res Treat. 2016;155:541-9.
    PubMed     Text format     Abstract available


    January 2016
  414. BERTRAND KA, Burian RA, Eliassen AH, Willett WC, et al
    Adolescent intake of animal fat and red meat in relation to premenopausal mammographic density.
    Breast Cancer Res Treat. 2016;155:385-93.
    PubMed     Text format     Abstract available


  415. BISWAS S, Atienza P, Chipman J, Blackford AL, et al
    A two-stage approach to genetic risk assessment in primary care.
    Breast Cancer Res Treat. 2016;155:375-83.
    PubMed     Text format     Abstract available


  416. QUILES F, Menendez M, Tornero E, del Valle J, et al
    Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA.
    Breast Cancer Res Treat. 2016;155:253-60.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: